EGFR and non-small cell lung carcinoma: The AURA-LM analysis examined the clinical efficacy of 80 mg of osimertinib daily as a second-line treatment for EGFR T790M-NSCLC patients and demonstrated an ORR of 55%, CR of 27%, median PFS of 11.1, and median OS of 18.8 months [23].